Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q4 and Year-End 2025 Earnings Presentation February 1 1, 2026 Safe Harbor and Forward-Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our produc ...

Group 1 - The company Novo Nordisk plans to launch its weight-loss pill Wegovy in vials [1]

We saw hims and hers come out with basically a copycat version of your oral GLP one. They since have scrapped that pill version and we saw the FDA come out and move pretty quickly against them. And so to start, I'm curious to know, were you surprised at just how quickly the FDA acted there.I was happy. I think that's a better word to use. We have for a long time been discussing how we simply don't understand how this compounding has gotten to the level that it has mass compounding.When when you see Super Bo ...

Core Viewpoint - The FDA's swift action against mass compounding practices is seen as a positive development for the industry, emphasizing the importance of patient safety and intellectual property rights [1][3][5]. Company Actions - The company has filed a lawsuit against Hims and Hers for patent infringement related to Semaglutide, despite Hims and Hers scrapping their pill version, indicating a commitment to protecting its intellectual property [4]. - The company emphasizes that compounding should be limited to specific cases rather than mass marketing, highlighting concerns over patient safety and the quality of active pharmaceutical ingredients (APIs) [5][6]. Market Dynamics - The company reported a successful launch of its oral GLP-1 pill, with 246,000 users within five weeks, significantly outperforming previous injectable launches [9][11]. - The initial price of the pill is set at $149, which is considered affordable, and the uptake has been 15 times better than the Wegovy injection launch [11][12]. - The company anticipates a year of pricing headwinds but expects volume growth to provide a tailwind in the future [10]. Manufacturing and Supply Chain - The pill is uniquely manufactured in the U.S. from start to finish, which is uncommon in the industry where many competitors source APIs from abroad [16][17]. Strategic Outlook - The company is actively seeking acquisition opportunities to enhance its R&D capabilities and is open to external innovations that complement its internal developments [18][19]. - Valuations of potential acquisition targets are well understood by the company, which maintains financial discipline in its bidding strategies [21][22]. - The timeline for potential deals is flexible, focusing on finding the right target rather than a specific quantity of deals [23].

Core Viewpoint - Universe Pharmaceuticals INC has successfully implemented a dual-class share structure, which will take effect on the Nasdaq Capital Market on February 13, 2026 [1]. Group 1: Dual-Class Share Structure - The company has amended and restated its memorandum and articles of association, changing its authorized share capital to US$20,000, divided into 1,800,000,000 Class A ordinary shares and 200,000,000 Class B ordinary shares, both with a par value of US$0.00001 each [2]. - The Class A Ordinary Shares will continue to trade under the symbol "UPC" and the same CUSIP number G9442G 138 starting from February 13, 2026 [3]. Group 2: Company Overview - Universe Pharmaceuticals INC is headquartered in Ji'an, Jiangxi, China, and specializes in the production and distribution of traditional Chinese medicine derivatives aimed at the elderly, addressing their physical conditions and promoting general well-being [4]. - The company also distributes biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements from third-party manufacturers, with products sold across 30 provinces in China [4].

Core Insights - Vanda Pharmaceuticals reported a strong financial performance for the full year 2025, with total revenues increasing by 9% to $216.1 million compared to 2024, driven primarily by a 24% increase in net product sales of Fanapt® [1][2] - The company is awaiting FDA approval for Bysanti™ (milsaperidone) for bipolar I disorder and schizophrenia, with a target action date of February 21, 2026, which could expand its psychiatry franchise [1][2] - The FDA approved NEREUS™ (tradipitant) for the prevention of motion-induced vomiting, marking a significant milestone as the first new oral therapy for this condition in over 40 years [1][2] Financial Highlights - For Q4 2025, Vanda reported a net loss of $141.2 million, compared to a net loss of $4.9 million in Q4 2024, with a diluted net loss per share of $2.39 [2][4] - The provision for income taxes in Q4 2025 was $103.2 million, influenced by a non-cash charge of $113.7 million against deferred tax assets [1][2] - Full year 2025 net loss was $220.5 million, compared to $18.9 million in 2024, with a diluted net loss per share of $3.74 [2][4] Operational Highlights - Fanapt® saw a 24% increase in net product sales for the full year 2025, totaling $117.3 million, supported by a 28% rise in total prescriptions [1][2] - The company launched a direct-to-consumer campaign in 2025, enhancing brand awareness for Fanapt® and PONVORY® [1][2] - Vanda is preparing for the commercial launch of NEREUS™ and plans to initiate a Phase III program for its use in preventing vomiting from GLP-1 analogs in the first half of 2026 [1][2] Regulatory & Clinical Development - Vanda received a decision letter from the FDA regarding the sNDA for HETLIOZ® for jet lag disorder, indicating it cannot be approved in its current form [2] - Ongoing clinical studies include a Phase III study of the long-acting injectable formulation of iloperidone for schizophrenia and a Phase III study of VQW-765 for social anxiety disorder [2] - The company submitted a BLA for imsidolimab for generalized pustular psoriasis in Q4 2025 [2] 2026 Financial Guidance - Vanda expects total revenues for 2026 to be between $230 million and $260 million, with Fanapt® net product sales projected to be between $150 million and $170 million [2]

Core Insights - Neurocrine Biosciences reported strong financial results for Q4 and full-year 2025, with net product sales of $798.3 million for Q4 and $2.83 billion for the full year, reflecting year-over-year growth of 29% and 22% respectively [1][2] - The company anticipates 2026 net product sales for INGREZZA to be between $2.7 billion and $2.8 billion, indicating continued growth potential [1][2] - The CEO emphasized the company's focus on sustainable growth and advancing its pipeline, including Phase 3 programs for osavampator and direclidine [1][2] Financial Performance - Q4 2025 net product sales for INGREZZA were $657.5 million, a 7% increase year-over-year, while full-year sales reached $2.51 billion, up 9% [1][2] - CRENESSITY's Q4 and full-year 2025 net product sales were $135.3 million and $301.2 million, respectively, with significant new patient enrollments [1][2] - Total revenues for Q4 2025 were $805.5 million, compared to $627.7 million in Q4 2024, and full-year revenues were $2.86 billion, up from $2.36 billion in 2024 [3][4] Research and Development Updates - The company initiated a Phase 2 clinical study for NBI-1065890, targeting tardive dyskinesia, leveraging its expertise in VMAT2 inhibition [1][2] - Neurocrine's R&D Day highlighted ongoing Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, indicating a robust pipeline [1][2] - The company is expanding its corticotropin releasing factor (CRF) platform to target metabolic diseases, including obesity [1][2] Market Position and Strategy - Neurocrine's strategic investments in R&D and commercial initiatives are aimed at supporting the growth of INGREZZA and the launch of CRENESSITY [2][3] - The company reported over 80% reimbursement coverage for CRENESSITY prescriptions, indicating strong market acceptance [1][2] - The financial guidance for 2026 reflects ongoing commercial initiatives and expansion of sales teams to support product growth [2][3]

Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers it’s lost to rival Eli Lilly & Co. https://t.co/qBY39J2Tij ...

Core Viewpoint - The FDA's refusal to review Moderna's application for its new mRNA flu vaccine has left the company's president in shock, citing confusion over the agency's decision regarding trial adequacy and control measures [1][6][7]. Group 1: FDA's Decision - The FDA stated that Moderna's application lacked an "adequate and well-controlled" trial, specifically not comparing the new vaccine to the best-available standard of care at the time of the study [2][9]. - The FDA indicated that the trial should have used a high-dose flu vaccine as a comparator, particularly for individuals over 65, as these are considered more effective for older adults [10][11]. - The FDA's letter did not express concerns about the safety or efficacy of the vaccine, but emphasized that the trial design did not meet their guidelines [6][9]. Group 2: Moderna's Response - Moderna's president expressed surprise and confusion over the FDA's decision, noting that the company had previously discussed trial designs with regulators and received written confirmation that their approach was acceptable [5][9]. - The company reportedly invested over a billion dollars in the clinical trial, which involved more than 40,000 participants and reached the pivotal Phase 3 stage [5][14]. - Moderna warned that the FDA's decision could deter future investments in new medicines and cures, suggesting a significant impact on innovation in the pharmaceutical industry [6]. Group 3: Implications and Reactions - The Health and Human Services spokesperson criticized Moderna for not following FDA guidance, stating that the trial exposed older participants to increased risks by using a substandard control [11][12]. - The recent policy changes under Health and Human Services Secretary Robert F. Kennedy, Jr. have led to the termination of nearly $500 million in federal funding for mRNA vaccine development, affecting multiple companies including Moderna [12][13]. - The decision has drawn criticism from health officials, who argue that it undermines the potential of mRNA vaccines in pandemic preparedness [13].

Core Viewpoint Novo Nordisk is facing significant challenges in the U.S. market due to competition from Eli Lilly and the rise of cheaper compounded versions of its weight-loss drug Wegovy. CEO Mike Doustdar has outlined a comprehensive strategy to navigate these challenges and aims for growth in 2026 despite the current headwinds. Group 1: Market Challenges - Novo Nordisk risks being edged out by Eli Lilly and the increasing number of patients using cheaper compounded versions of semaglutide, which are unapproved copies of Wegovy [2][8] - The company estimates that 1.5 million Americans are currently using these copycat weight-loss drugs, impacting its sales growth [8][12] - Doustdar acknowledged the challenges but expressed optimism for growth in 2026, stating that the company will have more patients and produce more than in previous years [3][7] Group 2: Product Performance - Approximately 246,000 patients are currently on Wegovy, which has outpaced the early rollouts of existing GLP-1 injections [5] - The Wegovy pill has shown an average weight loss of around 16.6%, compared to approximately 12.4% for Lilly's oral drug, indicating a significant efficacy advantage [20][27] - Doustdar emphasized that 88% of patients on the Wegovy pill are taking the lowest starter dose, suggesting a demand for oral options [18] Group 3: Competitive Landscape - Eli Lilly holds about 60% of the branded GLP-1 market globally, while Novo has around 39%, highlighting a competitive gap [16] - The compounded market shows a higher share of copycats for Novo's drug compared to Lilly's, raising questions about market dynamics [17] - Novo is preparing for increased competition as Lilly plans to launch its own oral weight-loss pill, orforglipron, in the second quarter of 2026 [19] Group 4: Regulatory and Legal Actions - Novo has initiated over 130 lawsuits against pharmacies and wellness clinics unlawfully marketing compounded versions of its drugs [12] - The FDA has announced a crackdown on compounding, which could potentially help Novo regain market share if successful [14][24] - Doustdar welcomed the government's acknowledgment of the compounding issue, viewing it as a strong signal for the company's efforts [14] Group 5: Future Strategies - Novo anticipates Medicare coverage for weight-loss treatments, which could open up a 15 million-patient opportunity [25] - The company is also focusing on next-generation treatments, including a higher dose of Wegovy and a new drug called CagriSema, which combines semaglutide with cagrilintide [26][28] - Doustdar believes that the higher dose of Wegovy could help the company compete more effectively against Lilly's Zepbound [27]